Drug Profile
Research programme: botulinum toxin antibodies - Humanyx
Latest Information Update: 30 Aug 2023
Price :
$50
*
At a glance
- Originator Humanyx
- Class Antibodies; Antitoxins
- Mechanism of Action Botulinum toxin inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Botulism
Most Recent Events
- 30 Aug 2023 Discontinued - Preclinical for Botulism in USA (Parenteral)
- 28 Mar 2020 No recent reports of development identified for preclinical development in Botulism in USA (Parenteral)
- 22 Feb 2016 Preclinical trials in Botulism in USA (Parenteral)